Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/20947
Title: Presymptomatic atrophy in autosomal dominant Alzheimer's disease: A serial magnetic resonance imaging study.
Austin Authors: Kinnunen, Kirsi M;Cash, David M;Poole, Teresa;Frost, Chris;Benzinger, Tammie L S;Ahsan, R Laila;Leung, Kelvin K;Cardoso, M Jorge;Modat, Marc;Malone, Ian B;Morris, John C;Bateman, Randall J;Marcus, Daniel S;Goate, Alison;Salloway, Stephen P;Correia, Stephen;Sperling, Reisa A;Chhatwal, Jasmeer P;Mayeux, Richard P;Brickman, Adam M;Martins, Ralph N;Farlow, Martin R;Ghetti, Bernardino;Saykin, Andrew J;Jack, Clifford R;Schofield, Peter R;McDade, Eric;Weiner, Michael W;Ringman, John M;Thompson, Paul M;Masters, Colin L ;Rowe, Christopher C ;Rossor, Martin N;Ourselin, Sebastien;Fox, Nick C
Affiliation: Department of Medical Statistics, London School of Hygiene & Tropical Medicine, London, UK
Department of Neurodegenerative Disease, Dementia Research Centre, UCL Institute of Neurology, London, UK
Department of Medical Physics and Bioengineering, Translational Imaging Group, Centre for Medical Image Computing, University College London, London, UK
Department of Neurology, Keck USC School of Medicine, Los Angeles, CA, USA
Department of Neurodegenerative Disease, Dementia Research Centre, UCL Institute of Neurology, London, UK
Centre of Excellence for Alzheimer's Disease Research and Care, School of Exercise, Biomedical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia
The Florey Institute, University of Melbourne, Parkville, Victoria, Australia
Imaging Genetics Center, Stevens Neuroimaging & Informatics Institute, Keck School of Medicine, University of Southern California, Marina del Rey, CA, USA
School of Medical Sciences, University of New South Wales, Sydney, NSW, Australia
Neuroscience Research Australia, Randwick, NSW, Australia
Department of Radiology, Washington University School of Medicine, St. Louis, MO, USA
Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA
Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, NY, USA
Department of Neurology, Butler Hospital, Warren Alpert Medical School, Brown University, Providence, RI, USA
Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
Department of Neurology, Columbia University Medical Center, New York, NY, USA
Department of Neurology, Indiana University School of Medicine, Indianapolis, IN, USA
Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, USA
Department of Radiology and Imaging Sciences, Centre for Neuroimaging, Indiana University School of Medicine, Indianapolis, IN, USA
Department of Radiology, Mayo Clinic, Rochester, MN, USA
Department of Radiology, School of Medicine, University of California, San Francisco, San Francisco, CA, USA
Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, Victoria, Australia
Issue Date: 2018
metadata.dc.date: 2017
Publication information: Alzheimer's & dementia : the journal of the Alzheimer's Association 2018; 14(1): 43-53
Abstract: Identifying at what point atrophy rates first change in Alzheimer's disease is important for informing design of presymptomatic trials. Serial T1-weighted magnetic resonance imaging scans of 94 participants (28 noncarriers, 66 carriers) from the Dominantly Inherited Alzheimer Network were used to measure brain, ventricular, and hippocampal atrophy rates. For each structure, nonlinear mixed-effects models estimated the change-points when atrophy rates deviate from normal and the rates of change before and after this point. Atrophy increased after the change-point, which occurred 1-1.5 years (assuming a single step change in atrophy rate) or 3-8 years (assuming gradual acceleration of atrophy) before expected symptom onset. At expected symptom onset, estimated atrophy rates were at least 3.6 times than those before the change-point. Atrophy rates are pathologically increased up to seven years before "expected onset". During this period, atrophy rates may be useful for inclusion and tracking of disease progression.
URI: http://ahro.austin.org.au/austinjspui/handle/1/20947
DOI: 10.1016/j.jalz.2017.06.2268
ORCID: 0000-0003-3910-2453
PubMed URL: 28738187
Type: Journal Article
Subjects: Alzheimer's disease
Atrophy
Autosomal dominant
Boundary Shift Integral
Change-point
Dementia
Longitudinal
MRI
Neuroimaging
Nonlinear modeling
Appears in Collections:Journal articles

Show full item record

Page view(s)

14
checked on Dec 2, 2022

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.